"The voice for cancer physicians and their patients in Massachusetts."

FDA approves durvalumab for locally advanced or metastatic biliary tract cancer

06 Sep 2022 8:51 AM | Katy Monaco (Administrator)

The Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer (BTC). More information

The attached document provides a summary of key results from the TOPAZ-1 trial, along with other important information about the use of IMFINZI in patients with advanced BTCs.

Massachusetts Society of Clinical Oncologists ©2022

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  Fax: 781.464.4896  |  email: msco@mms.org

Powered by Wild Apricot Membership Software